Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,034 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.
Thomas M, Kienast Y, Scheuer W, Bähner M, Kaluza K, Gassner C, Herting F, Brinkmann U, Seeber S, Kavlie A, Welschof M, Ries S, Weidner KM, Regula JT, Klein C. Thomas M, et al. PLoS One. 2013;8(2):e54923. doi: 10.1371/journal.pone.0054923. Epub 2013 Feb 6. PLoS One. 2013. PMID: 23405099 Free PMC article.
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.
Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, Gassner C, Georges G, Kettenberger H, Imhof-Jung S, Schwaiger M, Stubenrauch KG, Sustmann C, Thomas M, Scheuer W, Klein C. Schaefer W, et al. Among authors: thomas m. Proc Natl Acad Sci U S A. 2011 Jul 5;108(27):11187-92. doi: 10.1073/pnas.1019002108. Epub 2011 Jun 20. Proc Natl Acad Sci U S A. 2011. PMID: 21690412 Free PMC article.
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy.
Kienast Y, Klein C, Scheuer W, Raemsch R, Lorenzon E, Bernicke D, Herting F, Yu S, The HH, Martarello L, Gassner C, Stubenrauch KG, Munro K, Augustin HG, Thomas M. Kienast Y, et al. Among authors: thomas m. Clin Cancer Res. 2013 Dec 15;19(24):6730-40. doi: 10.1158/1078-0432.CCR-13-0081. Epub 2013 Oct 4. Clin Cancer Res. 2013. PMID: 24097868
Effect of Ang-2-VEGF-A Bispecific Antibody in Renal Cell Carcinoma.
Bessho H, Wong B, Huang D, Tan J, Ong CK, Iwamura M, Hart S, Dangl M, Thomas M, Teh BT. Bessho H, et al. Among authors: thomas m. Cancer Invest. 2015;33(8):378-86. doi: 10.3109/07357907.2015.1047505. Epub 2015 Jun 26. Cancer Invest. 2015. PMID: 26115098
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling.
Felcht M, Luck R, Schering A, Seidel P, Srivastava K, Hu J, Bartol A, Kienast Y, Vettel C, Loos EK, Kutschera S, Bartels S, Appak S, Besemfelder E, Terhardt D, Chavakis E, Wieland T, Klein C, Thomas M, Uemura A, Goerdt S, Augustin HG. Felcht M, et al. Among authors: thomas m. J Clin Invest. 2012 Jun;122(6):1991-2005. doi: 10.1172/JCI58832. Epub 2012 May 15. J Clin Invest. 2012. PMID: 22585576 Free PMC article.
11,034 results
You have reached the last available page of results. Please see the User Guide for more information.